Back to today’s briefing

Story perspectives

Study Links Shingrix Vaccine to 27% Reduced Dementia Risk

3/30/2025

27 3

Summary

Story summary

GSK is embarking on an ambitious four-year study involving 1.4 million NHS patients to explore whether its shingles vaccine, Shingrix, can significantly reduce the risk of dementia. Early findings suggest Shingrix may lower dementia risk by 27% compared to the older Zostervax vaccine, potentially offering hope to millions of older adults across the UK.

1 of 1

Story summary

GSK is embarking on an ambitious four-year study involving 1.4 million NHS patients to explore whether its shingles vaccine, Shingrix, can significantly reduce the risk of dementia. Early findings suggest Shingrix may lower dementia risk by 27% compared to the older Zostervax vaccine, potentially offering hope to millions of older adults across the UK.